Validation of group B borderline resectable pancreatic cancer: Retrospective analysis

Tak Geun Oh, Moon Jae Chung, Seungmin Bang, Seung Woo Park, Jae Bok Chung, Si Young Song, Jinsil Seong, Chang Moo Kang, Woo Jung Lee, Jeong Youp Park

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background/Aims: Among borderline resectable pancreatic cancer (BRPC), group B BRPC patients have findings that are suggestive but not diagnostic of metastasis. In this study, we attempted to validate whether group B could truly be categorized as a borderline resectable group. Methods: We placed the BRPC patients into group A or group B. The survival outcomes were compared between the groups. Results: A total of 53 patients with pancreatic adenocarcinoma was classified as either group A or B borderline resectable. In group A, 23 (60.5%) of 38 patients underwent pancreatectomy after concurrent chemoradiotherapy or chemotherapy, but in group B, only five (33.3%) of 15 patients underwent pancreatectomy, mainly because of the progression of suspected distant metastasis. There was a significant difference in overall survival (OS) between group A and B patients (median OS, 21.2 months vs 10.2 months, respectively; p=0.007). Of the patients who underwent pancreatectomy, group B had a higher recurrence rate compared to group A (recurrence rate: 11 of 23 patients [47.8%] vs five of five patients [100%], respectively; p=0.033). Conclusions: This report is the first to validate the definition of BPRC. Group B had much worse outcomes, and whether group B BRPC can be categorized as BRPC together with group A is questionable.

Original languageEnglish
Pages (from-to)557-562
Number of pages6
JournalGut and liver
Volume8
Issue number5
DOIs
Publication statusPublished - 2014 Sep

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Validation of group B borderline resectable pancreatic cancer: Retrospective analysis'. Together they form a unique fingerprint.

  • Cite this

    Oh, T. G., Chung, M. J., Bang, S., Park, S. W., Chung, J. B., Song, S. Y., Seong, J., Kang, C. M., Lee, W. J., & Park, J. Y. (2014). Validation of group B borderline resectable pancreatic cancer: Retrospective analysis. Gut and liver, 8(5), 557-562. https://doi.org/10.5009/gnl13264